Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
August 25, 2009
6.25% dividend yield. Hasn't done particularly well in participating in the recent rally. A solid play in a market where there is uncertainty.
Show full opinionHide full opinion
A T & T US (T-N)
August 25, 2009
6.25% dividend yield. Hasn't done particularly well in participating in the recent rally. A solid play in a market where there is uncertainty.
PAST TOP PICK
PAST TOP PICK
August 25, 2009
(A Top Pick March 3/09. Up 42.59%.)
Show full opinionHide full opinion
(A Top Pick March 3/09. Up 42.59%.)
PAST TOP PICK
PAST TOP PICK
August 25, 2009
(A Top Pick March 3/09. Up 38.07%.)
Show full opinionHide full opinion
Telefonica S.A. (TEF-N)
August 25, 2009
(A Top Pick March 3/09. Up 38.07%.)
PAST TOP PICK
PAST TOP PICK
August 25, 2009
(A Top Pick March 3/09. Up 10.73%.)
Show full opinionHide full opinion
TC Energy (TRP-T)
August 25, 2009
(A Top Pick March 3/09. Up 10.73%.)
COMMENT
COMMENT
August 25, 2009
Very well run bank. This is one of the US banks that he would look at and consider when he had little bit more confidence.
Show full opinionHide full opinion
Wells Fargo (WFC-N)
August 25, 2009
Very well run bank. This is one of the US banks that he would look at and consider when he had little bit more confidence.
COMMENT
COMMENT
August 25, 2009
Probably the best managed resource company globally. Tends to focus on cash flow, not production. Prefers Royal Dutch Shell (RDS.A-N) because they pay out dividends as opposed to share buyback. One of The most expensive of the companies in this space. He is not bullish on the price of oil from these levels.
Show full opinionHide full opinion
Exxon Mobil (XOM-N)
August 25, 2009
Probably the best managed resource company globally. Tends to focus on cash flow, not production. Prefers Royal Dutch Shell (RDS.A-N) because they pay out dividends as opposed to share buyback. One of The most expensive of the companies in this space. He is not bullish on the price of oil from these levels.
COMMENT
COMMENT
August 25, 2009
Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)
Show full opinionHide full opinion
Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)